Drug Profile
GX 051
Alternative Names: GX-051; GX-51Latest Information Update: 28 Mar 2018
Price :
$50
*
At a glance
- Originator Genexine
- Class Cancer vaccines; Cell therapies; Gene therapies; Immunotherapies; Mesenchymal stem cell therapies
- Mechanism of Action Interleukin 12 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Head and neck cancer
Most Recent Events
- 28 Mar 2018 Discontinued - Phase-I for Head and neck cancer (Late-stage disease) in South Korea (Intratumoural) (Genexine pipeline, March 2018)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Late-stage disease) in South Korea (Intratumoural, Injection)
- 01 Mar 2014 Phase-I clinical trials in Head and neck cancer (late-stage disease) in South Korea (Intratumoural) (NCT02079324)